Latest market price
6.83
-0.36-5.01%
OverviewShort InterestFilings
ACHVQT81Achieve Life Sciences, Inc.·NASDAQ
6.83-5.01%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TRAX-0.33%$45.08NVAX-3.72%$10.08NUVB-0.21%$4.76KLRA-4.10%$12.86REPL+1.27%$17.61STOK-0.23%$26.29QURE-1.86%$24.83NTLA-5.74%$12.47
Snapshot
Index—P/E—EPS (ttm)-1.55Insider Own—Shs Outstand102.90MPerf Week5.24%
Market Cap702.82MForward P/E—EPS next Y-0.68Insider Trans-0.03%Shs Float74.69MPerf Month-9.30%
Enterprise Value529.82MPEG—EPS next Q-0.20Short Float23.84%Perf Quarter8.07%
Income-114.00MP/S—EPS this Y—Short Ratio12.74Perf Half Y55.94%
Sales0.00P/B—EPS next Y—ROA-59.88%Short Interest17.81MPerf YTD37.42%
Book/sh-0.15P/C3.76EPS next 5Y—ROE—52W High8.64 -20.95%Perf Year37.98%
Cash/sh1.82P/FCF—EPS past 3/5Y—ROIC-21425.74%52W Low2.62 160.69%Perf 3Y69.06%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility5.89% 5.56%Perf 5Y-14.84%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)0.40Perf 10Y-99.18%
Dividend Ex-Date—Quick Ratio0.95Sales Y/Y TTM—Profit Margin0.00%RSI (14)46.41Recom2.00
Dividend Gr. 3/5Y—Current Ratio0.95EPS Q/Q-116.22%SMA20-0.47%Beta2.44Target Price15.25
Payout0.00%Debt/Eq—Sales Q/Q—SMA50-8.35%Rel Volume0.94Prev Close7.19
Employees28LT Debt/Eq—EarningsNov 05SMA20021.08%Avg Volume1.46MPrice6.83
IPO DateOct 12, 1995Option/ShortYes / YesEPS/Sales Surpr.-385.20% —Net Debt/EBITDA—Volume1,376,391Change-5.01%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-29-26InitiatedStifelBuy$18
Aug-13-26ReiteratedMorgan Stanley$13
Aug-12-26ReiteratedRaymond James$20 → $18
Aug-12-26ReiteratedH.C. WainwrightBuy$12
Jun-26-26ResumedRaymond JamesStrong Buy$20
Apr-20-26InitiatedCanaccordBuy$13
May-13-24ReiteratedOppenheimerOutperform$11
Nov-16-22ReiteratedMaxim GroupBuy$8.00
Latest News· Times ET
Oct-21-26
Oct-21-2608:30AM
Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026globenewswire.com
Oct-15-26
Oct-15-2608:41AM
Lisata adds biopharma finance veteran Jeffrey Farrow to boardYahoo
Oct-07-26
Oct-07-2608:30AM
Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communicationsglobenewswire.com
Oct-06-26
Oct-06-2604:02PM
Achieve Life Sciences Announces Granting of New Hire Inducement Awardsglobenewswire.com
Oct-02-26
Oct-02-2605:41AM
Achieve Life Sciences (NASDAQ:ACHV) Shares Gap Up – Here’s What Happeneddefenseworld.net
Oct-01-26
Oct-01-2608:30AM
Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officerglobenewswire.com
Sep-30-26
Sep-30-2601:34AM
Stifel Initiates Coverage On Achieve Life Sciences with Buy Rating, Announces Price Target of $18Benzinga
Sep-28-26
Sep-28-2608:30AM
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026globenewswire.com
Sep-23-26
Sep-23-2611:04AM
Achieve Life Sciences: Thesis Intact, Setup Remains Constructive (Rating Downgrade)seekingalpha.com
Sep-22-26
Sep-22-2607:25AM
Achieve Life Sciences: A Funded Manufacturing Reset, Not A Broken Clinical Thesisseekingalpha.com
Sep-21-26
Sep-21-2604:29AM
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Consensus Rating of “Buy” from Brokeragesdefenseworld.net
Sep-07-26
Sep-07-2604:20AM
Frazier Life Sciences Management L.P. Buys New Stake in Achieve Life Sciences, Inc. $ACHVdefenseworld.net
Sep-03-26
Sep-03-2605:15PM
Achieve Life Sciences Announced Granting of New Hire Inducement Awardsglobenewswire.com
Sep-02-26
Sep-02-2604:24AM
Deutsche Bank AG Makes New $506,000 Investment in Achieve Life Sciences, Inc. $ACHVdefenseworld.net
Aug-14-26
Aug-14-2612:31PM
Achieve Life Sciences Enters ATM Sale Agreement With Jefferies For Up To $150M In Common StockBenzinga
Company

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue
0000—————
Cost of Goods Sold Incl. D&A
0000—————
Gross Profit
0000—————
Selling, General and Administrative Excl. Other42321611—————
Research and Development16232316—————
Other Operating Expense
0000—————
Operating Income-58-55-39-27—————
Interest Expense0123—————
Unusual Expense
—————————
Non-Operating Income (Expense)-55110—————
Net Income Before Taxes-114-55-40-30—————
Income Taxes
0000—————
Consolidated Net Income-114-55-40-30—————
Net Income From Continuing Operations-114-55-40-30—————
Net Income-114-55-40-30—————
EPS (Recurring)-1.55-1.25-1.24-1.50—————
EPS (Basic, Before Extraordinaries)-1.55-1.25-1.24-1.50—————
EPS (Diluted)-1.55-1.25-1.24-1.50—————
EBITDA-112-54-37-27—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding94443220—————
Market Capitalization64221911382—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$9.41$7.50$5.59$3.68$1.77● Close Price0.00K43.79K87.59K131.38K175.18KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Stewart Richard AlistairDirectorAug 19 '26Sale8.4920,626175,177208,249Aug 21
Oki Mark KChief Financial OfficerSep 18 '25Option Exercise0.00168,0000178,000Sep 22
Oki Mark KChief Financial OfficerSep 18 '25Sale2.9250,060146,175127,940Sep 22
Stewart Richard AlistairChief Executive OfficerSep 18 '25Option Exercise0.00455,0000358,376Sep 22
Stewart Richard AlistairChief Executive OfficerSep 18 '25Sale2.92129,501378,143228,875Sep 22
Wan JerryPrincipal Accounting OfficerSep 04 '25Option Exercise0.0068,200046,764Sep 08
Wan JerryPrincipal Accounting OfficerSep 04 '25Sale2.7714,07038,97432,694Sep 08
KING THOMAS BRAXTONDirectorSep 04 '25Option Exercise0.00455,0000455,000Sep 08
KING THOMAS BRAXTONDirectorSep 04 '25Sale2.77139,858387,407315,142Sep 08
JACOBS CINDYPresident & CMOSep 04 '25Option Exercise0.00220,0000143,214Sep 08
JACOBS CINDYPresident & CMOSep 04 '25Sale2.7727,62976,532115,585Sep 08
Xinos JaimeChief Commercial OfficerSep 04 '25Option Exercise0.00138,000095,286Sep 08
Xinos JaimeChief Commercial OfficerSep 04 '25Sale2.7720,85457,76674,432Sep 08
Oki Mark KChief Financial OfficerMar 17 '25Buy2.8910,00028,88710,000Mar 19
Stewart Richard AlistairChieve Executive OfficerMar 17 '25Buy2.8610,00028,59860,876Mar 19
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.